Long Island Resident Rosalind Elam Treats Rare Brain Cancer Spread with Clinical Trial at NYU Langone

A 65-year-old Long Island resident, Rosalind Elam, demonstrated that timely diagnosis and enrollment in a specialized clinical trial can significantly impact survival and quality of life for patients facing high-grade serous carcinoma with leptomeningeal metastasis.

Following unusual headaches in March 2026, Elam began a four-week investigational treatment regimen at NYU Langone Health, leading to a significant reduction in cancer cells detected in her cerebrospinal fluid.

This case study highlights the vital role of precision oncology in managing aggressive, rare cancers. Leptomeningeal metastasis is a complex condition where malignant cells spread to the meninges—the membranes protecting the brain and spinal cord. For patients facing this, standard treatment options are often limited; therefore, access to novel, experimental therapies through clinical trials becomes a critical lifeline.

Leptomeningeal Metastasis Treated with Azeliragon and Radiation

  • The Problem: Leptomeningeal metastasis is cancer that has spread to the protective coverings of the brain and spinal cord, causing severe neurological symptoms.
  • The Solution: Elam’s treatment combined an investigational medication, azeliragon, with targeted radiation to the brain and spine.
  • The Result: This targeted approach successfully reduced the measurable number of cancer cells in her cerebrospinal fluid, allowing her to maintain an active, independent lifestyle.

Rosalind Elam’s journey began in March 2026 when she noticed persistent, unusual headaches. Because she was a long-time patient at NYU Langone Health’s Perlmutter Cancer Center, her oncologist, Alexander A. Hindenburg, MD, quickly prioritized her symptoms and referred her to neuro-oncologists. This proactive approach is a key public health message: recognizing deviation from one’s normal baseline is often the first step toward life-saving intervention.

“Dr. Hindenburg and I are close, and he understands me so well. When I told him about my headaches, he had me schedule an MRI as soon as possible and referred me to Dr. Gewirtz. I'm very grateful to him,” Rosalind Elam said.

The diagnosis of high-grade serous carcinoma with leptomeningeal metastasis confirmed the seriousness of her condition. This cancer spreads not just locally but through the fluid surrounding the central nervous system (CNS). Such spread can result in debilitating symptoms, including vision and hearing changes, loss of bowel or bladder control, and profound weakness.

Dr. Gewirtz, the neuro-oncologist managing her case, noted the importance of patient self-awareness. “It’s important for patients to understand their bodies so they know when something is off. Seeking care early can make a huge difference,” Dr. Gewirtz said, emphasizing that early detection dramatically improves prognosis even for aggressive cancers.

Azeliragon Targets Molecular Pathways to Disrupt Cancer Growth

The turning point in Elam’s care was her enrollment in a clinical trial led by Dr. Jonathan Yang, MD, PhD. This trial focused on the use of azeliragon, an investigational medication, administered in combination with radiation directed at the brain and spine. This combination therapy is designed to disrupt the cancer cell’s ability to grow and spread throughout the CNS.

Azeliragon belongs to a class of drugs that function by targeting specific molecular pathways within cancer cells. By inhibiting these pathways, the medication aims to starve or deactivate the malignant cells, even those that have scattered into the protective meningeal spaces. The goal of such a trial is to test the therapeutic index—the balance between efficacy (how well it works) and toxicity (how much harm it causes).

Within the four-week trial period that began in April 2026, Elam’s response was highly encouraging. Her care team reported a significant decrease in cancer cells detected in her cerebrospinal fluid. This data suggests that the combination of azeliragon and radiation effectively halted the metastatic spread of the carcinoma, providing a durable response to what is typically a high-risk diagnosis.

The trial’s design requires rigorous, continuous monitoring. Participants, including Elam, undergo regular MRI scans of the brain and spine, as well as cerebrospinal fluid analysis. This level of surveillance ensures that the drug is not only effective but also manageable, allowing the medical team to promptly identify and mitigate potential adverse effects.

Treatment Component Drug Classification Primary Target Therapeutic Goal (Clinical)
Azeliragon Investigational Small Molecule Specific Cancer Pathways Inhibition of tumor growth and spread
Radiation Therapy Physical Oncology Localized Tumor Cells (Brain/Spine) Cellular destruction of metastatic sites

Global Context and Regulatory Oversight

The success of this treatment highlights the increasing global focus on personalized medicine. While this trial took place at NYU Langone Health, the methodology and resulting data are critical for larger, multi-national regulatory bodies. For instance, findings like these will eventually inform submissions to agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as the investigational drug moves toward broader application.

Clinical Trial Risks and Patient Advocacy Emphasized

While the outcome for Rosalind Elam has been positive, it is crucial to understand that clinical trial participation carries inherent risks. This four-week clinical trial evaluated azeliragon, an investigational medication, in combination with radiation to the brain and spine for patients with leptomeningeal metastasis.

Elam emphasized the importance of patient advocacy, advising peers to “ask about alternative treatment options that are available, and write down your questions.” This self-advocacy is not just a personal choice; it is a critical component of modern oncology, ensuring that every patient is an active participant in their care strategy.

Elam’s care took place within one of the Northeast’s largest academic health systems. NYU Langone Health traces its origins to 1841, when the Medical College of New York University was founded with an inaugural class of 239 students; among its six original faculty members was the renowned surgeon Valentine Mott, MD. Today the system spans New York and Florida, with more than 400 locations, seven inpatient facilities and over 55,000 employees.

Its Long Island presence is especially relevant to Elam’s story: in 2019, the system acquired Winthrop University Hospital in Mineola, renaming it NYU Langone Hospital—Long Island, and in 2025 it fully acquired Long Island Community Hospital, now NYU Langone Hospital—Suffolk. The medical school itself was renamed NYU Grossman School of Medicine in 2019, and in 2013 it became the first nationally ranked medical school to introduce a Three-Year MD Program.

As Elam continues her treatment with Enhertu, she remains in a state of active management rather than cure. Her story is not one of definitive victory, but of successful, intensive management that has restored quality of life while addressing the underlying malignancy. “The clinical trial process was great. I felt how invested the staff members and care team were in my well-being,” she shared with the NYU Langone team.

References

  • NYU Langone Health, Perlmutter Cancer Center (2026).
  • Vizient Inc. (2026).
  • PubMed. (2026).
Photo of author

Health Desk

Health Desk at Archyde.

Barcelona’s ‘Real’ Derby Draws 16,430 Fans to Espanyol’s Stadium

A Few Good Men Review: Stage Revival Feels Smaller Than the Film